Get access

Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease

  • Protocol
  • Intervention



This is the protocol for a review and there is no abstract. The objectives are as follows:

This review aims to look at the benefits and harms of CERA compared with other epoetins (darbepoetin alfa and erythropoietin alfa or beta) or placebo/no treatment for anaemia in individuals with CKD.

Get access to the full text of this article